TRIP6 and ovarian clear cell cancer: Interestingly, this phenomenon mirrors the findings in ovarian clear cell carcinoma, where ARID1A mutations are associated with promoter hypermethylation and transcriptional repression of downstream targets such as IRX1, TMEM101, and TRIP6 (Li et al., 2024).